Company Overview
About INBRAIN Neuroelectronics
INBRAIN Neuroelectronics is a neurotechnology company founded in 2019 as a spin-out from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, Spain. The company develops minimally invasive brain-computer interfaces built on graphene — a single layer of carbon atoms with exceptional electrical conductivity, biocompatibility, and transparency to MRI imaging. INBRAIN's graphene electrodes enable higher spatial resolution neural sensing and more precise, adaptive stimulation than conventional metal electrodes used in implantable neurostimulators.
Business Model & Competitive Advantage
The company raised €30M in a Series B round in 2024, with investors including Neurotech Capital and other European deeptech funds, bringing total funding to over €50M. INBRAIN's clinical strategy focuses on neuromodulation indications with high unmet need: Parkinson's disease, epilepsy, treatment-resistant depression, and obsessive-compulsive disorder. Its AI-driven signal processing layer enables closed-loop stimulation — the device reads neural signals, interprets them with machine learning algorithms, and adjusts stimulation parameters in real time to optimize therapeutic effect, personalizing treatment to each patient's moment-to-moment brain state.
Competitive Landscape 2025–2026
INBRAIN has achieved first-in-human implantation milestones and is advancing through clinical development under regulatory oversight in Europe. The company's graphene interface technology has applications beyond therapeutic neuromodulation — including brain-computer interfaces for motor rehabilitation and future neurocognitive augmentation — positioning INBRAIN at the frontier of both medical device regulation and emerging neural interface technology. The company collaborates with academic medical centers and neurosurgical teams across Europe to generate the clinical evidence required for CE Mark approval.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare INBRAIN Neuroelectronics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from INBRAIN Neuroelectronics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim INBRAIN Neuroelectronics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention INBRAIN Neuroelectronics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →